GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are associated with early-onset, severe allergic ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech for small-molecule monovalent glue medicine ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Orionis to receive $105 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for the discovery of small-molecule monovale ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...